Risk of Acute Kidney Injury in Living Liver Donor Surgery
NCT ID: NCT05255510
Last Updated: 2022-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
130 participants
OBSERVATIONAL
2019-10-10
2021-06-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation
NCT02079350
Cardiovascular-Renal Consequences of Reducing Renal Mass After Living Kidney Donation
NCT01564966
Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney
NCT02059460
Angiotensin 2 for AKI After OLT
NCT04592744
Renal and Cardiac Risk Factors of AKI After Liver Transplantation
NCT05666232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based only on the serum creatinine increase, AKI occurs in 5-15% of hepatectomy patients.In this study, we aimed to evaluate the incidence of AKI based on the change of serum creatinine levels in living liver donor hepatectomy regarding intraoperative fluid restriction targeting low CVP levels and high PPV and SPV depending on our protocolized fluid management.
130 living liver donors were admitted for a retrospective observational study. The low central venous pressure (\<5 mmHg) and high pulse pressure variation (PPV\<20%) / systolic pressure variation (SPV\<15%) were applied to reduce intraoperative blood loss as fluid management until the end of the hepatic parenchymal division. AKI was defined using the KDIGO criteria according to the serum creatinine. The SPSS 11.5 program was used for statistical analysis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elvan Onur Kırımker
UNKNOWN
Sevcan Büyük
UNKNOWN
Elif Beyza Baskan
UNKNOWN
Ali Abbas Yılmaz
UNKNOWN
Deniz Balcı
UNKNOWN
Kaan Karayalçın
UNKNOWN
Mustafa Kemal Bayar
UNKNOWN
Ankara University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Süheyla Karadağ Erkoç
Anesthesiology and Reanimation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Süheyla Karadağ Erkoç
Role: PRINCIPAL_INVESTIGATOR
Ankara University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Süheyla Karadağ Erkoç
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AnkaraUni
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.